Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy
Surgery is the main treatment for localized prostate cancer. The most common technique is a
"radical prostatectomy," which involves removing the prostate gland, seminal vesicles and
nearby lymph nodes. Radical prostatectomy is a major operation, most suitable for otherwise
healthy men whose cancer does not appear to have spread.One of the most technically
challenging aspects of this surgery is reconstruction of the interrupted urinary tract by
hand suturing the bladder neck anastomosis, in which the bladder neck is sewn to the urethra
after the prostate has been removed.
CONTINUUM™ (study Device) is a surgical device intended to be used as part of the radical
prostatectomy procedure. The Device facilitates approximation of the bladder neck and
urethral stump by bringing together and holding the tissue in place until adequate natural
healing of the vesico-urethral anastomosis occurs. CONTINUUM™ also approximates the bladder
and urethral stump to minimize extravasation, while simultaneously providing a conduit for
drainage of urine from the bladder while the anastomotic site heals.
The concept of the CONTINUUM™ device and the feasibility of its operation have been tested
in animal and human studies. Pilot clinical studies in the United States (G060095) found
that the majority of Subjects who received and were discharged with the Device demonstrated
a water-tight vesico-urethral anastomosis at the first Device removal visit. Additionally,
no unanticipated adverse device effects (UADEs) were reported. The intent of this study is
to verify CONTINUUM™ device performance across a variety of US sites and physicians using
updated CONTINUUM™ device design modifications and physician training methodology on Device
implant and removal techniques prior to initiation of a randomized US Pivotal study.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety
At Device placement, Device removal, 4 weeks post-Device removal, 6 months post-Device removal
Yes
Naveen Kella, MD
Principal Investigator
Urology San Antonio Research PA
United States: Food and Drug Administration
PE0814
NCT00894933
May 2009
December 2010
Name | Location |
---|---|
Urology Clinics of North Texas | Dallas, Texas 75231 |
Arkansas Urology | Little Rock, Arkansas 72211 |
Lahey Clinic Medical Center | Burlington, Massachusetts 01805 |
Center for Urology | Rochester, New York 14619 |
Urologic Consultants of Southeastern Pennsylvania | Philadelphia, Pennsylvania 19004 |
Urology San Antonio Research PA | San Antonio, Texas 78205 |